MedTrace Logo

Adavosertib and Gemcitabine in Advanced Pancreatic

NCT05212025 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-14

No results posted yet for this study

Summary

This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer.

The names of the study drugs involved in this study are:

* Adavosertib
* Gemcitabine

Conditions

Interventions

DRUG

Adavosertib

Taken Orally

DRUG

Gemcitabine

Intravenous Infusion

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Lustgarten Foundation

    collaborator OTHER

  • Stand Up To Cancer

    collaborator OTHER

  • James Cleary, MD, PhD

    lead OTHER

Principal Investigators

  • James Cleary, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-06-01
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212025 on ClinicalTrials.gov